Patient and Provider Fact Sheets
- Paxlovid (U.S. Office of the Assistant Secretary for Preparedness and Response)
- Lagevrio (Molnupiravir) (ASPR)
- Veklury (remdesivir) (ASPR)
Products With the Potential to Address Future COVID-19 Variants Not Currently Authorized
- REGEN-COV (U.S. Office of the Assistant Secretary for Preparedness and Response)
- Sotrovimab (ASPR)
- Evusheld (ASPR)
- Bebtelovimab (ASPR)
Clinical Resources and Information
- COVID-19 therapeutics decision aid (PDF) (U.S. Office of the Assistant Secretary for Preparedness and Response)
- Side-by-side overview of mAb therapeutics (PDF) (ASPR)
- What's new in treatment guidelines (National Institutes of Health)
Guidance for Health Care Providers
State Resources
- Overview of WA State Order Process for COVID-19 Therapeutics (PDF)
- Apple Health (Medicaid) monoclonal antibody treatment for COVID-19 clinical policy (PDF) (Health Care Authority)
- Therapeutics Information for Health Care Providers
- Free Telehealth Appointments for COVID-19 Treatment
Federal Resources
- COVID-19 Therapeutic Product Expiration (U.S. Department of Health and Human Services)
- Fact Sheet: HHS Announces Intent to Amend the Declaration Under the PREP Act for Medical Countermeasures Against COVID-19 (U.S. Department of Health and Human Services)
- Claims Reimbursement to Providers and Facilities - Frequently Asked Questions (Health Resources & Services Administration)
- Subcutaneous administration factsheet (PDF) (U.S. Department of Health and Human Services)
- Medicare reimbursement information (U.S. Centers for Medicare & Medicaid Services)
- HRSA Health Center COVID-19 Therapeutics Program Participants (Health Resources & Services Administration)
- Uninsured Program Fact Sheet (PDF) (Health Resources & Services Administration)
- Statement on Patient Prioritization for Outpatient Therapies (National Institutes of Health)
Literature
- Realizing the Potential of Anti–SARS-CoV-2Monoclonal Antibodies for COVID-19 Management (Rajesh T. Gandhi, MD, Massachusetts General Hospital)
- Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities (The Journal of Infectious Diseases)
- Management of Drug Interactions With Nirmatrelvir/Ritonavir (Paxlovid®): Resource for Clinicians (Infectious Diseases Society of America)
- Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir against mortality, hospitalization, and in-hospital outcomes among community-dwelling, ambulatory COVID-19 patients during the BA.2.2 wave in Hong Kong: an observational study (MedRxiv)
- Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk Patients (Oxford Academic)
- Nirmatrelvir Resistant SARS-CoV-2 Variants with High Fitness in Vitro (BioRxiv)
- Dispensing of Oral Antiviral Drugs for Treatment of COVID-19 by Zip Code-Level Social Vulnerability- United States, December, 23 2021-August 28,2022 (CDC)
- Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment- California, December 2021-May 2022 (CDC)
- Long COVID (CDC)